CPT code 83505 identifies a quantitative laboratory assay for total hydroxyproline, usually measured in a 24-hour urine specimen to evaluate collagen turnover and bone metabolic activity. Nationally, this specialized biochemical test is relevant for monitoring conditions that affect collagen degradation and bone remodeling, including metabolic bone disease and disorders that alter collagen metabolism. Its use informs clinical decisions about bone activity and disease progression rather than serving as a general screening tool.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, common sites of service, and the role of the assay in diagnostic workflows. The publication summarizes how payers typically position coverage for specialized biochemical assays and provides benchmarking context where available. Topics addressed include clinical indications for ordering the test, typical laboratory workflows, and payer considerations relevant to coverage and claims processing.

This nationally focused summary is intended for clinicians, laboratory directors, and billing professionals who need a clear description of what CPT code 83505 represents, why the assay matters clinically, and what to expect operationally when this test is ordered.